Trial Profile
Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms SONCAR
- 22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium
- 21 Mar 2021 Planned End Date changed from 1 Jan 2025 to 1 Dec 2025.
- 21 Mar 2021 Status changed from recruiting to active, no longer recruiting.